Under construction – not a live service
Sign in
Not yet taking people in ChinaNo phase

Reflux After Sleeve Gastrectomy, With and Without Omentopexy, in People With Obesity

Compares sleeve gastrectomy with or without omentopexy for reflux in adults with obesity.

Plain-language title generated from the registry record
Registry title: De Novo Gastroesophageal Reflux Disease After Sleeve Gastrectomy With and Without Omentopexy

Key facts

Where
Beijing, ChinaSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Source: NCT07854613, who can take part

Where in China

  • China-Japan Friendship HospitalBeijing, ChinaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
China-Japan Friendship Hospital
Trial code
NCT07854613
Record updated
15 October 2026
Original description
The goal of this clinical trial is to compare the effects of sleeve gastrectomy with and without omentopexy on gastroesophageal reflux disease (GERD) in patients with obesity. The main question it aims to answer is:Read full original descriptionShow less

Comparative Effects of Sleeve Gastrectomy With and Without Omentopexy on Gastroesophageal Reflux Disease in Patients With Obesity

The goal of this clinical trial is to compare the effects of sleeve gastrectomy with and without omentopexy on gastroesophageal reflux disease (GERD) in patients with obesity. The main question it aims to answer is:

Does the addition of omentopexy to sleeve gastrectomy reduce the incidence of postoperative GERD compared with sleeve gastrectomy alone, as measured by the proportion of participants with a postoperative GERD-Q score ≥8?

Researchers will compare sleeve gastrectomy with omentopexy to sleeve gastrectomy without omentopexy to determine whether omentopexy reduces the incidence of postoperative GERD.

Participants will:

Undergo sleeve gastrectomy with or without omentopexy according to their randomized treatment assignment.

Complete the GERD-Q questionnaire after surgery to assess gastroesophageal reflux symptoms.

Attend postoperative follow-up visits for assessment of GERD and other clinical outcomes.

Inclusion: Adults aged 18 to 65 years; Body mass index (BMI) ≥32.5 kg/m²; Participants who meet the clinical indications for sleeve gastrectomy for the treatment of obesity; Participants who are willing to undergo sleeve gastrectomy and comply with the study protocol and postoperative follow-up schedule.

Exclusion: Previous bariatric surgery; Preoperative gastroesophageal reflux disease (GERD), defined by any of the following:; GERD-Q score ≥8; Regular use of high-dose proton pump inhibitors (PPIs) for the management of reflux symptoms; Patient-reported typical symptoms of gastroesophageal reflux, including heartburn or acid regurgitation; Hiatal hernia identified by preoperative upper gastrointestinal endoscopy; Reflux esophagitis classified as Los Angeles grade B, C or D on preoperative upper gastrointestinal endoscopy; Barrett's esophagus.

ClinicalTrials.gov NCT07854613